Press Release Jan 07 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The application is eligible for Accelerated Assessment due to the urgent medical need it addresses, particularly for resistant Gram-negative infections. The drug has also been submitted for review by the US FDA and has completed pivotal clinical trials.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Wockhardt
- Press Release Dec 31 2025
- Press Release Dec 01 2025
- Press Release Nov 03 2025
- Press Release Oct 01 2025
- Press Release Sep 25 2025
Later from Wockhardt
- Wockhardt Limited Press Release Jan 27 2026
- Press Release Feb 10 2026
- Wockhardt Limited Press Release Mar 30 2026
- Press Release May 04 2026
- Press Release May 28 2026
Follow Wockhardt into a list and get an email when it puts out news.
Follow Wockhardt